Orthogrid Systems Inc., of Salt Lake City, has received a green light from the U.S. FDA for the latest application on its intraoperable PhantomMSK platform, this one for use in orthopedic trauma cases. The new PhantomMSK Trauma application, which Orthogrid plans to formally roll out next spring, joins currently available applications for total hip and hip preservation. The Trauma application is an orthopedic surgical software that helps surgeons achieve and confirm the alignment of bone fractures and improves intraoperative efficiency via artificial intelligence-trained and augmented reality-based decision support and assistance for the placement of surgical instruments.
Spinal cord stimulation to treat pain has long been associated with mixed efficacy and substantial side effects such as paresthesia, which is an unpleasant tingly or prickly sensation. Redwood City, Calif.-based Nevro Corp. famously has built a multi-billion-dollar business on next-gen, pain neurostimulation technology that improves efficacy and reduces side effects. Sommerville, Mass.-based Micro-leads Medical Inc. hopes that it could be next in successfully further refining spinal cord stimulation.
PARIS – Dentressangle Initiative SAS, of Lyon, France, is in talks to buy a majority stake in Marle International Holding SAS, an orthopedic implant contract manufacturer. The acquisition is said to be worth $880 million, although Dentressangle has not confirmed this amount. “We are looking forward to supporting the management team in achieving its long-term goal for Marle, of offering higher value-added services to its clients and pursuing target acquisitions,” Thierry Coloigner, managing partner for mid and large cap at Dentressangle, told BioWorld MedTech.